- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05638581
Reanimación de traumatismos con sangre entera o productos del grupo O de título bajo (TROOP)
The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.
The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.
The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- University of Alabama at Birmingham, UAB Hospital
-
-
California
-
Los Angeles, California, Estados Unidos, 90033
- Los Angeles County + University of Southern California (LAC + USC) Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70112
- University Medical Center New Orleans LCMC Health
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- University of Maryland Medical Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Atrium Health Wake Forest Baptist
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45267
- University of Cincinnati Medical Center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Sciences University Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Penn Presbyterian Medical Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- University of Texas Health Science Center Houston
-
San Antonio, Texas, Estados Unidos, 78229
- University of Texas Health San Antonio and University Health System
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- Harborview Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Froedtert Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)
-
Patient taken to trauma center directly from scene
-
Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting
-
Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol
-
Traumatic injury with at least one of the following:
- Confirmed or suspected acute major bleeding
- Assessment of Blood Consumption (ABC) Score ≥2
Exclusion Criteria:
- Patients who have received, prehospital or in-hospital more than two units of LTOWB; the equivalent in components (two units of packed red blood cells and two units of plasma); or a combination of the two (more than one unit of LTOWB, one unit of packed cells, and one unit of plasma). Most trauma centers hold two units of either packed red blood cells (with two units of plasma) or two units of LTOWB in the emergency department. This stock is used to initiate transfusion, while the massive hemorrhage protocol is activated from the blood bank.
- Patients transferred from another hospital
- Children <15 years (in most communities, patients aged 15-18 years are treated at adult trauma centers, and patients in this age group frequently suffer life-threatening injuries, and will therefore be included)
- Known prisoners, defined as individuals involuntarily confined or detained in a penal institution (including juvenile detention, involuntary psychiatric commitment, or court-ordered residential substance abuse treatment)
- Moribund patients expected to die within 1 hour
- Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
- Patients with known "do not resuscitate" orders prior to randomization
- Patients who refuse the administration of blood products
- Individuals with a research "opt out" bracelet.
- Greater than 20% total body surface area (TBSA) burns
- Suspected inhalation injury victims
- Patients who are obviously pregnant on clinical examination or known to be pregnant as provided by the subject or legally authorized representative
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: LTOWB
Participants randomized to receive (Low Titer O Whole Blood [LTOWB]) |
Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously. |
|
Comparador activo: Components
Participants randomized to receive the component blood products. |
Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
6-hour Mortality
Periodo de tiempo: First 6 hours after randomization
|
Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant) |
First 6 hours after randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
24-hour Mortality
Periodo de tiempo: First 24 hours after randomization
|
Participant vital status at 24-hours following randomization |
First 24 hours after randomization
|
|
Hospital/30-day Mortality
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier) |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Incidence of Pre-specified Complications
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Adjudicated Primary Cause of Death
Periodo de tiempo: 30-days post randomization
|
Primary cause of death as reviewed and determined by the study investigators (consensus) |
30-days post randomization
|
|
Length of Stay (Hospital and Intensive Care Unit)
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Number of hours hospitalized (includes both hospital and intensive care unit time) |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Hospital-, Ventilator- and Intensive Care Unit-free days
Periodo de tiempo: 30-days post randomization
|
Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit. |
30-days post randomization
|
|
Incidence of major surgical procedures
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
The proportion of participants undergoing major surgical procedures. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Time to hemostasis in those undergoing procedures with a hemostatic component
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization
Periodo de tiempo: First 24 hours after randomization
|
The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.) |
First 24 hours after randomization
|
|
Discharge destination
Periodo de tiempo: At hospital discharge or 30-days post randomization (whichever the earlier)
|
Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc. |
At hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Functional status
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Patient's quality of life
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jan Jansen, MBBS, PhD, University of Alabama at Birmingham
Publicaciones y enlaces útiles
Publicaciones Generales
- Meizoso JP, Cotton BA, Lawless RA, Kodadek LM, Lynde JM, Russell N, Gaspich J, Maung A, Anderson C, Reynolds JM, Haines KL, Kasotakis G, Freeman JJ. Whole blood resuscitation for injured patients requiring transfusion: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2024 Sep 1;97(3):460-470. doi: 10.1097/TA.0000000000004327. Epub 2024 Mar 27.
- Jansen JO, Pedroza C, Novelo LL, Hao T, DeWildt GR, Coton CF, Mansoor K, Stephens SW, Marques MB, Stubbs JR, Richter JR, Wang HE, Holcomb JB, DeSantis SM. Trauma resuscitation with Low-Titer Group O Whole Blood Or Products: study protocol for a randomized clinical trial (the TROOP trial). Trials. 2025 Aug 2;26(1):266. doi: 10.1186/s13063-025-08971-y.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB-300010517
- 1UG3HL157401-01A1 (Subvención/contrato del NIH de EE. UU.)
- 1U24HL157310-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .